Skip to main content

Advertisement

SpringerLink
Log in

A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

Recent studies have shown the combination of C-reactive protein (CRP) and albumin (The modified Glasgow Prognostic Score, mGPS) had prognostic value in some solid tumors. However, no studies have examined its prognostic role in small-cell lung cancer (SCLC) patients. In this retrospective study, 460 consecutive SCLC patients were screened. Eligible patient was assigned a mGPS of 0, 1, or 2 based on pre-treatment plasma CRP and albumin (0: CRP ≤ 10 mg/L; 1: CRP >10 mg/L and albumin ≥ 35 g/L; 2: CRP > 10 mg/L and albumin < 35 g/L). Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors for SCLC. A total of 359 patients were analyzed. The mGPS of 0, 1, and 2 was assigned to 66.3, 30.6, and 3.1 % of total patients. For patients with mGPS of 0, 1, and 2, median overall survival (OS) was 30.4, 28.2, and 14.3 months, respectively (P < 0.001). Performance status (P < 0.001), disease stage (P < 0.001) and pre-treatment LDH (P < 0.001) also significantly predicted OS. Multivariate analyses showed mGPS was an independent prognostic factor (P < 0.001). This study demonstrated that higher mGPS independently predicts worse OS for SCLC patients. The assessment of mGPS could assist the identification of patients with poor prognosis and be a hierarchical factor in the future SCLC clinical trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.20107.

    Article  PubMed  Google Scholar 

  2. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist. 2007;12(9):1096–104. doi:10.1634/theoncologist.12-9-1096.

    Article  PubMed  Google Scholar 

  3. Simos D, Sajjady G, Sergi M, Liew MS, Califano R, Ho C, et al. Third-line chemotherapy in small-cell lung cancer: an international analysis. Clin Lung Cancer. 2014;15(2):110–8. doi:10.1016/j.cllc.2013.11.003.

    Article  CAS  PubMed  Google Scholar 

  4. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111(6):1710–7.

    Article  CAS  PubMed  Google Scholar 

  5. Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist. 2010;15(2):187–95. doi:10.1634/theoncologist.2009-0298.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Ma M, Wang M, Xu Y, Hu K, Liu H, Li L, et al. First-line chemotherapy and its survival analysis of 394 patients with extensive-stage small cell lung cancer in a single institute. Zhongguo Fei Ai Za Zhi. 2014;17(1):8–14. doi:10.3779/j.issn.1009-3419.2014.01.02.

    PubMed  Google Scholar 

  7. Li J, Dai CH, Chen P, Wu JN, Bao QL, Qiu H, et al. Survival and prognostic factors in small cell lung cancer. Med Oncol. 2010;27(1):73–81. doi:10.1007/s12032-009-9174-3.

    Article  CAS  PubMed  Google Scholar 

  8. Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89(3):523–33.

    Article  CAS  PubMed  Google Scholar 

  9. Fizazi K, Cojean I, Pignon JP, Rixe O, Gatineau M, Hadef S, et al. Normal serum neuron specific enolase (NSE) value after the first cycle of chemotherapy: an early predictor of complete response and survival in patients with small cell lung carcinoma. Cancer. 1998;82(6):1049–55.

    Article  CAS  PubMed  Google Scholar 

  10. Mantovani A. Cancer: inflaming metastasis. Nature. 2009;457(7225):36–7. doi:10.1038/457036b.

    Article  CAS  PubMed  Google Scholar 

  11. Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi:10.1093/jnci/dju124.

    Article  PubMed  Google Scholar 

  12. Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–12. doi:10.1158/1055-9965.EPI-14-0146.

    Article  CAS  PubMed  Google Scholar 

  13. Laird BJ, Kaasa S, McMillan DC, Fallon MT, Hjermstad MJ, Fayers P, et al. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system. Clin Cancer Res. 2013;19(19):5456–64. doi:10.1158/1078-0432.CCR-13-1066.

    Article  CAS  PubMed  Google Scholar 

  14. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006;94(5):637–41. doi:10.1038/sj.bjc.6602998.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006;94(2):227–30. doi:10.1038/sj.bjc.6602922.

    Article  CAS  PubMed  Google Scholar 

  16. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;67(3):257–62. doi:10.1017/s0029665108007131.

    Article  PubMed  Google Scholar 

  17. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89(6):1028–30. doi:10.1038/sj.bjc.6601242.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45. doi:10.1016/S0140-6736(00)04046-0.

    Article  CAS  PubMed  Google Scholar 

  19. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. doi:10.1038/nature01322.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Hwang EC, Hwang IS, Yu HS, Kim SO, Jung SI, Hwang JE, et al. Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer. Jpn J Clin Oncol. 2012;42(10):955–60. doi:10.1093/jjco/hys124.

    Article  PubMed  Google Scholar 

  21. Oremek GM, Sauer-Eppel H, Bruzdziak TH. Value of tumour and inflammatory markers in lung cancer. Anticancer Res. 2007;27(4A):1911–5.

    CAS  PubMed  Google Scholar 

  22. Hong S, Kang YA, Cho BC, Kim DJ. Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer. Yonsei Med J. 2012;53(1):111–7. doi:10.3349/ymj.2012.53.1.111.

    Article  PubMed  Google Scholar 

  23. Suh SY, Ahn HY. Lactate dehydrogenase as a prognostic factor for survival time of terminally ill cancer patients: a preliminary study. Eur J Cancer. 2007;43(6):1051–9. doi:10.1016/j.ejca.2007.01.031.

    Article  CAS  PubMed  Google Scholar 

  24. Petrovic M, Bukumiric Z, Zdravkovic V, Mitrovic S, Atkinson HD, Jurisic V. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer. Med Oncol. 2014;31(2):823. doi:10.1007/s12032-013-0823-1.

    Article  PubMed  Google Scholar 

  25. Zhao WX, Luo JF. Serum neuron-specific enolase levels were associated with the prognosis of small cell lung cancer: a meta-analysis. Tumour Biol. 2013;34(5):3245–8. doi:10.1007/s13277-013-0896-7.

    Article  CAS  PubMed  Google Scholar 

  26. Emin Erbaycu A, Gunduz A, Batum O, Zeren Ucar Z, Tuksavul F, Zeki Guclu S. Pre-treatment and treatment-induced neuron-specific enolase in patients with small-cell lung cancer: an open prospective study. Arch Bronconeumol. 2010;46(7):364–9. doi:10.1016/j.arbres.2010.04.005.

    Article  PubMed  Google Scholar 

  27. Leifsson BG, Ahren B. Serum calcium and survival in a large health screening program. J Clin Endocrinol Metab. 1996;81(6):2149–53. doi:10.1210/jcem.81.6.8964843.

    CAS  PubMed  Google Scholar 

  28. Temme EH, Zhang J, Schouten EG, Kesteloot H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control. 2001;12(10):887–94.

    Article  CAS  PubMed  Google Scholar 

  29. Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004;30(3):261–77. doi:10.1385/ir:30:3:261.

    Article  PubMed  Google Scholar 

  30. Casamassima A, Picciariello M, Quaranta M, Berardino R, Ranieri C, Paradiso A, et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J Urol. 2005;173(1):52–5. doi:10.1097/01.ju.0000146713.50673.e5.

    Article  CAS  PubMed  Google Scholar 

  31. Hara M, Yonei A, Ayabe T, Tomita M, Nakamura K, Onitsuka T. Postoperative serum C-reactive protein levels in non-small cell lung cancer patients. Ann Thorac Cardiovasc Surg. 2010;16(2):85–90.

    PubMed  Google Scholar 

  32. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004;90(9):1704–6. doi:10.1038/sj.bjc.6601789.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Color Dis. 2007;22(8):881–6. doi:10.1007/s00384-006-0259-6.

    Article  Google Scholar 

  34. Proctor MJ, Morrison DS, Talwar D, Balmer SM, Fletcher CD, O’Reilly DS, et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer. 2011;47(17):2633–41. doi:10.1016/j.ejca.2011.03.028.

    Article  PubMed  Google Scholar 

  35. Leung EY, Scott HR, McMillan DC. Clinical utility of the pretreatment Glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol. 2012;7(4):655–62. doi:10.1097/JTO.0b013e318244ffe1.

    Article  PubMed  Google Scholar 

  36. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223–6. doi:10.1097/MCO.0b013e32832a7902.

    Article  PubMed  Google Scholar 

  37. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–63. doi:10.2217/fon.09.136.

    Article  CAS  PubMed  Google Scholar 

  38. Roxburgh CS, Crozier JE, Maxwell F, Foulis AK, Brown J, McKee RF, et al. Comparison of tumour-based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients undergoing curative resection for colon cancer. Br J Cancer. 2009;100(5):701–6. doi:10.1038/sj.bjc.6604926.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

This work was supported by: Wu Jieping Medical Foundation Project (Grant No. 08-JC-003), Innovative drug R & D center based on real-time high-throughput cell-based screening platform and large capacity compound library (Grant No. 2013ZX09401003-002), National Natural Science Funds of China (Grant No. 81372502) and National High Technology Research and Development Program of China (Grant No. 2012AA02A502). All the grant supporters have no roles in study design, data collection and analysis, and manuscript preparation.

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651# Dongfeng East Road, Guangzhou, China, 510060

    Ting Zhou, Shaodong Hong, Zhihuang Hu, Xue Hou, Yan Huang, Hongyun Zhao, Wenhua Liang, Yuanyuan Zhao, Wenfeng Fang, Xuan Wu, Tao Qin & Li Zhang

  2. State Key Laboratory of Oncology in South China, Guangzhou, China

    Ting Zhou, Shaodong Hong, Zhihuang Hu, Xue Hou, Yan Huang, Hongyun Zhao, Wenhua Liang, Yuanyuan Zhao, Wenfeng Fang, Xuan Wu, Tao Qin & Li Zhang

  3. Collaborative innovation Center for Cancer Medicine, Guangzhou, China

    Ting Zhou, Shaodong Hong, Zhihuang Hu, Xue Hou, Yan Huang, Hongyun Zhao, Wenhua Liang, Yuanyuan Zhao, Wenfeng Fang, Xuan Wu, Tao Qin & Li Zhang

Authors
  1. Ting Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shaodong Hong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhihuang Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xue Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hongyun Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Wenhua Liang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yuanyuan Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Wenfeng Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xuan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Tao Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Li Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Li Zhang.

Additional information

Ting Zhou and Shaodong Hong contributed equally to this work and share the first authorship.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, T., Hong, S., Hu, Z. et al. A systemic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer. Tumor Biol. 36, 337–343 (2015). https://doi.org/10.1007/s13277-014-2623-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2623-4

Keywords

Search

Navigation